Product Images Victoza
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 23 images provide visual information about the product associated with Victoza NDC 0169-4060 by Novo Nordisk, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Figure 1: Structural Formula of liraglutide - 49f302f5 f315 48b8 83a4 6ca56f01fded 01
Figure 2 Mean Insulin Secretion Rate (ISR) versus Glucose Concentration - 49f302f5 f315 48b8 83a4 6ca56f01fded 02
Figure 4 Mean HbA1c for patients who completed the 26-week trial and for the Last Observation Carried Forward (LOCF, intent-to-treat) data at Week 26 - 49f302f5 f315 48b8 83a4 6ca56f01fded 04
Victoza Pen and Needle - image 01
This seems to be a visual guide or diagram for the Victoza pen, showing the different parts and components of the device, such as the rubber cartridge tip, stopper, display, and needle. The text also provides a phone number and website for troubleshooting assistance.*
Figure: Pull off Pen Cap - image 02
Figure: Attaching Needle - image 03
Figure: Remove Outer Needle Cap - image 04
Figure: Remove Inner Needle Cap - image 05
Figure: Turn Dose Selector to Flow Check Symbol - image 06
Figure: Tap Cartridge Gently with Finger - image 07
Figure: Keep Needle Pointing Up and Press Dose Button - image 08
Figure: Pull Off Pen Cap - image 09
Figure: Attaching Needle - image 10
Figure: Remove Outer Needle Cap - image 11
Figure: Remove Inner Needle Cap - image 12
Figure: Turn Dose Selector To Dose - image 13
Figure: 0.6 mg, 1.2 mg and 1.8 mg Dose - image 14
Figure: Delivering the Dose - image 15
Keep dose button pressed down for 6 seconds. - image 16
Figure: Withdraw the Needle - image 17
Figure: Safely Remove the Needle - image 18
Figure 5 - image 20
The text describes a comparison between the drug Victoza and a placebo over a course of 54 months in a full analysis set. The data includes the number of patients at risk for each treatment at different time points. The HR (hazard ratio) is given as 0.87 with a 95% CI (confidence interval) of 0.78 to 0.97.*
Figure 3 - image 21
This is a graph comparison between Glimepiride and VICTOZA 1.2mg over time (weeks) with an additional comparison of VICTOZA 1.8mg. The values obtained are significant, with a p-value less than 0.0001 for VICTOZA 1.8mg compared to both Glimepiride and VICTOZA 1.2mg. ANCOVA was used to analyze the data.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.